Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates
Open accessAbstract
Messenger RNA (mRNA) vaccine technology has shown its power in preventing the ongoing COVID-19 pandemic. Two mRNA vaccines targeting the full-length S protein of SARS-CoV-2 have been authorized for emergency use. Recently, we have developed a lipid nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor-binding domain (RBD) of SARS-CoV-2 (termed ARCoV), which confers complete protection in mouse model. Herein, we further characterized the protection efficacy of ARCoV in nonhuman primates and the long-term stability under normal refrigerator temperature. Intramuscular immunization of two doses of ARCoV elicited robust neutralizing antibodies as well as cellular response against SARS-CoV-2 in cynomolgus macaques. More importantly, ARCoV vaccination in macaques significantly protected animals from acute lung lesions caused by SARS-CoV-2, and viral replication in lungs and secretion in nasal swabs were completely cleared in all animals immunized with low or high doses of ARCoV. No evidence of antibody-dependent enhancement of infection was observed throughout the study. Finally, extensive stability assays showed that ARCoV can be stored at 2-8 °C for at least 6 months without decrease of immunogenicity. All these promising results strongly support the ongoing clinical trial.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ArCoV can be stored at room temperature for at least 1 week, as confirmed in preclinical studies.
“The developers emphasize thermostability, as their vaccine can be stored at room temperature for at least 1 week, which was confirmed in preclinical studies.140,141”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [141]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884 · see citing works
Self-citationYang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066 · see citing works
Self-citationVirological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661 · cited 1× · see citing works
“As previously mentioned, subgenomic RNA (sgRNA) was used to quantify RNA replication in nasal swabs, lung, and trachea specimens.(17) The limit of detection was the lowest level at which viral RNA can be specifically amplified in this assay (Ct value of 38).”
MethodStructural basis for the recognition of SARS-CoV-2 by full-length human ACE2
Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020) · Science · doi:10.1126/science.abb2762 · Cited by 4,950 · see citing works
Self-citationGenome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China
Wu, A., Peng, Y., Huang, B., Ding, X. L., Wang, X., Niu, P., Meng, J., Zhu, Z., Zhang, Z., Wang, J., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.02.001 · Cited by 2,363 · see citing works
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312 · see citing works
Self-citationSARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098 · see citing works
Development of an inactivated vaccine candidate for SARS-CoV-2
Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434 · see citing works
Self-citationRobust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195 · see citing works
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024671 · Cited by 1,066 · see citing works
Self-citationChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J. N., Port, J. R., Avanzato, V. A., Bushmaker, T., Flaxman, A., Ulaszewska, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2608-y · Cited by 914 · see citing works
Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model
Rockx, B., Kuiken, T., Herfst, S., Bestebroer, T., Lamers, M. M., Oude Munnink, B. B., de Meulder, D., van Amerongen, G., van den Brand, J., Okba, N. M. A., et al. (2020) · Science · doi:10.1126/science.abb7314 · Cited by 901 · see citing works
Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L. H., et al. (2020) · Nature · doi:10.1038/s41586-020-2607-z · Cited by 789 · see citing works
Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1743767 · Cited by 711 · see citing works
Self-citationNew SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications
Abdool Karim, S. S., & de Oliveira, T. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2100362 · Cited by 699 · cited 1× · see citing works
“Currently, SARS-CoV-2 variants of concern were linked to higher transmissibility and the potential immune escape from medical countermeasures.(20) NAbs of sera from individuals vaccinated with BNT162b2 were 4.”
BackgroundBNT162b vaccines protect rhesus macaques from SARS-CoV-2
Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03275-y · Cited by 694 · see citing works
A thermostable mRNA vaccine against COVID-19
Zhang, N.-N., Li, X.-F., Deng, Y.-Q., Zhao, H., Huang, Y.-J., Yang, G., Huang, W.-J., Gao, P., Zhou, C., Zhang, R.-R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.024 · Cited by 671 · cited 10× · see citing works
“Recently, we have developed a novel COVID-19 mRNA vaccine candidate, ARCoV, based on the established lipid nanoparticles (LNPs) encapsulated mRNA platform.(14) ARCoV was designed to carry mRNA encoding the RBD of SARS-CoV-2, and two doses of”
BackgroundMethodInfluentialSelf-citationA systematic review of SARS-CoV-2 vaccine candidates
Dong, Y., Dai, T., Wei, Y., Zhang, L., Zheng, M., & Zhou, F. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00352-y · Cited by 541 · see citing works
Alberer, M., Gnad-Vogt, U., Hong, H. S., Mehr, K. T., Backert, L., Finak, G., Gottardo, R., Bica, M. A., Garofano, A., Koch, S. D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31665-3 · Cited by 530 · see citing works
Addressing the Cold Reality of mRNA Vaccine Stability
Crommelin, D. J. A., Anchordoquy, T. J., Volkin, D. B., Jiskoot, W., & Mastrobattista, E. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.12.006 · Cited by 517 · see citing works
The potential danger of suboptimal antibody responses in COVID-19
Iwasaki, A., & Yang, Y.-X. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0321-6 · Cited by 510 · see citing works
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent
Mazzoni, A., Salvati, L., Maggi, L., Capone, M., Vanni, A., Spinicci, M., Mencarini, J., Caporale, R., Peruzzi, B., Antonelli, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138554 · Cited by 502 · see citing works
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
Wall, E. C., Wu, M., Harvey, R., Kelly, G., Warchal, S., Sawyer, C., Daniels, R., Hobson, P., Hatipoglu, E., Ngai, Y., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01290-3 · Cited by 491 · see citing works
Feldman, R. A., Fuhr, R., Smolenov, I., (Mick) Ribeiro, A., Panther, L., Watson, M., Senn, J. J., Smith, M., Almarsson, Ӧ., Pujar, H. S., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.074 · Cited by 454 · see citing works
mRNA vaccine: a potential therapeutic strategy
Wang, Y., Zhang, Z., Luo, J., Han, X., Wei, Y., & Wei, X. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01311-z · Cited by 422 · see citing works
Lederer, K., Castaño, D., Gómez Atria, D., Oguin, T. H., Wang, S., Manzoni, T. B., Muramatsu, H., Hogan, M. J., Amanat, F., Cherubin, P., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.11.009 · Cited by 383 · cited 1× · see citing works
“Immunization with mRNA vaccine encoding the SARSCoV-2 RBD was demonstrated to elicit robust NAbs and memory T, B cell responses in rodents without the detection of antibodydependent enhancement (ADE) of infection.(6,7) More than 130 vaccine candidates against SARS-CoV-2 are in clinical development, and at least 55 of…”
BackgroundLaczko, D. I., Hogan, M. J., Toulmin, S. A., Hicks, P. D., Lederer, K., Gaudette, B. T., Castaño, D., Amanat, F., Muramatsu, H., Oguin, T. H., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.019 · Cited by 366 · see citing works
Effectiveness of Mask Wearing to Control Community Spread of SARS-CoV-2
Brooks, J. T., & Butler, J. C. (2021) · JAMA · doi:10.1001/jama.2021.1505 · Cited by 354 · see citing works
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
Li, D., Edwards, R. J., Manne, K., Martinez, D. R., Schäfer, A., Alam, S. M., Wiehe, K. J., Lu, X., Parks, R., Sutherland, L. L., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.021 · Cited by 331 · see citing works
Self-citationAn infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies
Liu, Y., Soh, W. T., Kishikawa, J.-I., Hirose, M., Nakayama, E. E., Li, S., Sasai, M., Suzuki, T., Tada, A., Arakawa, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.05.032 · Cited by 270 · see citing works
Schmitt, M., Schewe, M., Sacchetti, A., Feijtel, D., van de Geer, W. S., Teeuwssen, M., Sleddens, H. F. B. M., Joosten, R., van Royen, M. E., van de Werken, H. J. G., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.085 · Cited by 237 · see citing works
Pawlowski, C., Lenehan, P. J., Puranik, A., Agarwal, V., Venkatakrishnan, A., Niesen, M. J. M., O’Horo, J. C., Virk, A., Swift, M. D., Badley, A. D., et al. (2021) · Med · doi:10.1016/j.medj.2021.06.007 · Cited by 185 · see citing works
A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
Sánchez-Felipe, L., Vercruysse, T., Sharma, S., Ma, J., Lemmens, V., Looveren, D. V., Javarappa, M. P. A., Boudewijns, R., Malengier‐Devlies, B., Liesenborghs, L., et al. (2020) · Nature · doi:10.1038/s41586-020-3035-9 · Cited by 174 · see citing works
Self-citationComparison of rhesus and cynomolgus macaques as an infection model for COVID-19
Salguero, F. J., White, A., Slack, G. S., Fotheringham, S. A., Bewley, K. R., Gooch, K. E., Longet, S., Humphries, H. E., Watson, R. J., Hunter, L. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21389-9 · Cited by 155 · see citing works
Leal, L., Guardo, A. C., Morón‐López, S., Salgado, M., Mothe, B., Heirman, C., Pannus, P., Vanham, G., van den Ham, H., Gruters, R. A., et al. (2018) · AIDS · doi:10.1097/qad.0000000000002026 · Cited by 100 · see citing works
Zang, J., Gu, C., Zhou, B., Zhang, C., Yang, Y., Xu, S., Bai, L., Zhang, R., Deng, Q., Yuan, Z., et al. (2020) · Cell Discovery · doi:10.1038/s41421-020-00199-1 · Cited by 67 · see citing works
Self-citationLi, Y., Bi, Y., Xiao, H., Yao, Y., Liu, X., Hu, Z., Duan, J., Yang, Y., Li, Z., Li, Y., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1887767 · Cited by 45 · see citing works
Self-citationHow epidemiology has shaped the COVID pandemic
(2021) · Nature · doi:10.1038/d41586-021-00183-z · Cited by 35 · see citing works
Löffler, C., Mahrhold, J., Fogarassy, P., Beyer, M., & Hellmich, B. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.06.051 · Cited by 15 · see citing works
Bordoni, V., Viola, D., Sacchi, A., Pinnetti, C., Casetti, R., Cimini, E., Tumino, N., Antinori, A., Ammassari, A., & Agrati, C. (2018) · Cytokine · doi:10.1016/j.cyto.2017.12.033 · Cited by 9 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
COVID-19 mRNA vaccines: Platforms and current developments
Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308 · see citing works
mRNA vaccines in disease prevention and treatment
Zhang, G., Tang, T., Chen, Y., Huang, X., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01579-1 · Cited by 253 · see citing works
The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case
Blenke, E. O., Örnskov, E., Schöneich, C., Nilsson, G. Å., Volkin, D. B., Mastrobattista, E., Almarsson, Ö., & Crommelin, D. J. A. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.11.001 · Cited by 214 · see citing works
Research Advances on the Stability of mRNA Vaccines
Cheng, F., Wang, Y., Bai, Y., Liang, Z., Mao, Q., Liu, D., Wu, X., & Xu, M. (2023) · Viruses · doi:10.3390/v15030668 · Cited by 171 · see citing works
Ai, L., Li, Y., Zhou, L., Yao, W., Zhang, H., Hu, Z., Han, J., Wang, W., Wu, J., Xu, P., et al. (2023) · Cell Discovery · doi:10.1038/s41421-022-00517-9 · Cited by 148 · see citing works
Self-citationApplications of liposomes and lipid nanoparticles in cancer therapy: current advances and prospects
Cheng, Z., Huang, H., Yin, M., & Liu, H. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00602-1 · Cited by 155 · see citing works
mRNA nanomedicine: Design and recent applications
Kubiatowicz, L. J., Mohapatra, A., Krishnan, N., Fang, R. H., & Zhang, L. (2022) · Exploration · doi:10.1002/exp.20210217 · Cited by 130 · see citing works
Wu, L., Li, X., Qian, X., Wang, S., Liu, J., & Yan, J. (2024) · Vaccines · doi:10.3390/vaccines12020186 · Cited by 125 · see citing works
Self-citationBiomimetic noncationic lipid nanoparticles for mRNA delivery
Wang, C., Zhao, C., Wang, W., Liu, X., & Deng, H. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2311276120 · Cited by 91 · see citing works
A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability
Voigt, E. A., Gerhardt, A., Hanson, D., Jennewein, M. F., Battisti, P., Reed, S., Singh, J., Mohamath, R., Bakken, J., Beaver, S., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00549-y · Cited by 89 · see citing works
A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery
Gerhardt, A., Voigt, E. A., Archer, M. C., Reed, S., Larson, E., Hoeven, N. V., Kramer, R. M., Fox, C. B., & Casper, C. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.009 · Cited by 86 · see citing works
Hashiba, K., Taguchi, M., Sakamoto, S., Otsu, A., Maeda, Y., Ebe, H., Arimichi, O., Harashima, H., & Sato, Y. (2024) · Communications Biology · doi:10.1038/s42003-024-06235-0 · Cited by 84 · see citing works
Does CCL19 act as a double-edged sword in cancer development?
Shabgah, A. G., Al-Obaidi, Z. M. J., Rahman, H. S., Abdelbasset, W. K., Suksatan, W., Bokov, D. O., Thangavelu, L. P., Jalil, A. T., Jadidi-Niaragh, F., Mohammadi, H., et al. (2021) · Clinical & Experimental Immunology · doi:10.1093/cei/uxab039 · Cited by 74 · see citing works
A preparation method for mRNA-LNPs with improved properties
Geng, C., Zhou, K., Yan, Y., Li, C., Ni, B., Liu, J., Wang, Y., Zhang, X., Wang, D., Lv, L., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.11.017 · Cited by 71 · see citing works
Self-citationRapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant
Zhang, N., Zhang, R., Zhang, Y., Ji, K., Xiong, X.-C., Qin, Q., Gao, P., Lu, X., Zhou, H., Song, H., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00626-w · Cited by 56 · see citing works
Self-citationNebulised delivery of RNA formulations to the lungs: From aerosol to cytosol
Neary, M. T., Mulder, L. M., Kowalski, P. S., MacLoughlin, R. J., Crean, A. M., & Ryan, K. B. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.012 · Cited by 62 · see citing works
Rational development of a combined mRNA vaccine against COVID-19 and influenza
Ye, Q., Wu, M., Chao Hui, Z. H. O. U., Lu, X., Huang, B., Zhang, N., Zhao, H. J., Chi, H., Zhang, X., Ling, D., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00478-w · Cited by 51 · see citing works
Self-citationmRNA vaccines in the prevention and treatment of diseases
Gu, Y., Duan, J., Yang, N., Yang, Y., & Zhao, X. (2022) · MedComm · doi:10.1002/mco2.167 · Cited by 51 · see citing works
Design and lyophilization of mRNA-encapsulating lipid nanoparticles
Wang, T., Yu, T., Li, W., Liu, Q., Sung, T., & Higuchi, A. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124514 · Cited by 41 · see citing works
Self-citationHengelbrock, A., Schmidt, A., & Strube, J. (2023) · Processes · doi:10.3390/pr11061718 · Cited by 33 · see citing works
A Minimalist Pathogen‐Like Sugar Nanovaccine for Enhanced Cancer Immunotherapy
Yu, M., Niu, L., Lv, X., Zhang, Q., Xiao, Z., Ji, Z., Chen, L., Liu, Y., Liu, N., Zhu, J., et al. (2024) · Advanced Materials · doi:10.1002/adma.202410715 · Cited by 29 · see citing works
Shirane, D., Tanaka, H., Sakurai, Y., Taneichi, S., Nakai, Y., Tange, K., Ishii, I., & Akita, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071819 · Cited by 28 · see citing works
Zamani, P., Mashreghi, M., Bazaz, M. R., Zargari, S., Alizadeh, F. L., Dorrigiv, M., Abdoli, A., Aminianfar, H., Hatamipour, M., Zarqi, J., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.025 · Cited by 24 · see citing works
Reprogramming cellular senescence and aging clocks for advanced cancer immunotherapy
Yang, H., Liu, D., Qiu, L., Wang, R., Zhang, C., Yu, D., Zhong, Q., Yuki, N., Song, Z., Zhu, Τ., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02459-8 · Cited by 24 · see citing works
SWI/SNF-type complexes–transcription factor interplay: a key regulatory interaction
Maassen, A., Steciuk, J., Wilga, M., Szurmak, J., Garbicz, D., Sarnowska, E. A., & Sarnowski, T. J. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-025-00704-y · Cited by 23 · see citing works
The impact of chemical reactivity on the quality and stability of RNA–LNP pharmaceuticals
Kovačič, T., Haas, H., Stotsky‐Oterin, L., Štrancar, A., Bren, U., & Peer, D. (2025) · Nature Reviews Chemistry · doi:10.1038/s41570-025-00763-x · Cited by 20 · see citing works
Neutralizing Efficacy of Encapsulin Nanoparticles against SARS-CoV2 Variants of Concern
Khaleeq, S., Sengupta, N., Kumar, S., Patel, U. R., Rajmani, R., Reddy, P., Pandey, S., Singh, R., Dutta, S., Ringe, R. P., et al. (2023) · Viruses · doi:10.3390/v15020346 · Cited by 18 · see citing works
Yang, X., Chi, H., Wu, M., Wang, Z., Lang, Q., Han, Q., Wang, X., Liu, X., Li, Y., Wang, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992787 · Cited by 18 · see citing works
Self-citationCOVID-19 Vaccines: Where Did We Stand at the End of 2023?
Lundstrom, K. H. (2024) · Viruses · doi:10.3390/v16020203 · Cited by 19 · see citing works
Advancements in the development of nucleic acid vaccines for syphilis prevention and control
Li, S., Li, W., Jin, Y., Wu, B., & Wu, Y. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2234790 · Cited by 15 · see citing works
Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines
Hromić‐Jahjefendić, A., Lundstrom, K. H., Adilović, M., Aljabali, A. A. A., Tambuwala, M. M., Serrano‐Aroca, Á., & Uversky, V. N. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103508 · Cited by 13 · see citing works
Wang, S., Guo, B., Wang, H., & Yang, F. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105547 · Cited by 13 · see citing works
Wang, T., Yu, T., Li, W., Chen, J., Cheng, S., Tian, Z., Sung, T., & Higuchi, A. (2025) · Regenerative Biomaterials · doi:10.1093/rb/rbaf023 · Cited by 13 · see citing works
Self-citationNanotechnology-Based RNA Vaccines: Fundamentals, Advantages and Challenges
Pozharov, V. P., & Minko, T. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010194 · Cited by 12 · see citing works
Circular RNA Telomerase Reverses Endothelial Senescence in Progeria
Qin, W., Castillo, K., Li, H., Nguyen, T. K. C., Kiss, D., Cooke, J. P., & Mojiri, A. (2025) · Aging Cell · doi:10.1111/acel.70021 · Cited by 10 · see citing works
Advances in mRNA-LNP lung-targeted delivery strategies
Liu, X., Ji, S., Cai, Y., Yang, F., You, J., & Luo, L. (2025) · Microstructures · doi:10.20517/microstructures.2024.172 · Cited by 10 · see citing works
Wen, Z., Fang, C., Liu, X., Liu, Y., Li, M., Yuan, Y., Han, Z., Wang, C., Zhang, T., & Sun, C. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2171233 · Cited by 9 · see citing works
Liu, J., Xia, Y., Tian, C., Chen, Z., Guo, W., Liu, Y., Wen, J. A., Xie, Z., Lin, J., Li, J., et al. (2025) · Journal of Virology · doi:10.1128/jvi.00978-25 · Cited by 8 · see citing works
Recent advances in freeze-drying technologies for mRNA vaccines against infectious diseases
Lou, J., Wu, Z., Cheng, Y., Li, M., Liu, N., Wang, Z., Gao, X., Zheng, A., & Zhang, H. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126426 · Cited by 9 · see citing works
Hannawi, S., Wu, X., Villalobos, R. E., Burhan, E., Borra, M. D. L., Gupta, R. K., Aquitania, G. P., Ang, B. W., Zabat, G. M. A., Roa, C. C., et al. (2024) · Med · doi:10.1016/j.medj.2024.06.013 · Cited by 8 · see citing works
Self-citationSarkar, D., Pramanik, A., Das, D., & Bhattacharyya, S. (2024) · Inflammation Research · doi:10.1007/s00011-024-01918-0 · Cited by 7 · see citing works
COVID-19 and Parkinson’s Disease: Possible Links in Pathology and Therapeutics
Tiwari, S., Yadav, N., & Singh, S. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00540-4 · Cited by 7 · see citing works
Rational Combinations of PARP Inhibitors with HRD-Inducing Molecularly Targeted Agents
Lee, E. K., & Liu, J. F. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-30065-3_10 · Cited by 6 · see citing works
Alternative Structural Lipids Impact mRNA-Lipid Nanoparticle Morphology, Stability, and Activity
Thorn, C. R., Hickey, J. C., Chi, Y., Wang, M. M., Huang, K. N., Hong, S., Zou, Q., Nguyen, H.-M., Pak, R. H., & Soo, P. L. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00824 · Cited by 5 · see citing works
Advances in mRNA vaccines for viral diseases
Huang, Y., Zhu, X., Guo, X., Zhou, Y., Liu, D., Mao, J., Xiong, Y., Deng, Y., & Gao, X. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28924 · Cited by 5 · see citing works
Self-citationZhou, C., Sun, M., Huang, X., Liu, P., Ouyang, Z., Wu, M., Yuan, L., Chen, J., Shu, W., Cao, T., et al. (2025) · hLife · doi:10.1016/j.hlife.2025.04.008 · Cited by 4 · see citing works
Self-citationHara, S., Suzuki, T., Mizogaki, I., Miyazaki, T., Kondo, K., Arase, S., Suzuki, Y., Sato, S., & Ukai, K. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.104031 · Cited by 3 · see citing works
Identification of SARS-CoV-2-binding lectins on a commercial lectin array
Neetu, N. A., Ahlawat, S., Delipan, R., Ringe, R. P., Rao, A., & Ramya, T. N. C. (2025) · Scientific Reports · doi:10.1038/s41598-025-01903-5 · Cited by 2 · see citing works
He, C., Tang, C., Guo, J., Yin, X., Zhu, Q., & Fang, C. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06983-5 · Cited by 2 · see citing works
Wen, J., Moon, J., Tucciarone, L., Bu, T.-H., Sun, A. Y., Miller, R., Timis, J., Wu, L., Smith, D. M., Shresta, S., et al. (2026) · npj Vaccines · doi:10.1038/s41541-026-01421-z · Cited by 2 · see citing works
The hidden half of lipid nanoparticle manufacturing: Downstream processing
Sagmeister, P., Devos, C., Udepurkar, A. P., Schwenger, A., Webb, C., McDonald, A., Berry, M., Zydney, A. L., Braatz, R. D., & Myerson, A. S. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115189 · Cited by 2 · see citing works
Immunobiology and immunotherapy of COVID-19
Lundstrom, K. H. (2025) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.12.002 · Cited by 3 · see citing works
Applications of Spray-Dried Vaccines
Arpagaus, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-24323-3_6 · Cited by 1 · see citing works
Sathe, N., Shaikh, S., Bhavsar, M., Parte, L., Gadiparthi, A., Kad, S., Sensarma, S., Nalband, H., Sangapillai, R., Sivashanmuganathan, S., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.10.006 · Cited by 1 · see citing works
Liquid–liquid phase separation in normal hematopoiesis and hematological diseases
Lin, L., He, F., Xu, J., Zhang, X., Li, Y., Wang, D., Wang, J., Zheng, L., Song, H., Zhu, X. H., et al. (2025) · Cell and Tissue Research · doi:10.1007/s00441-025-03974-2 · Cited by 1 · see citing works
Self-citationComparisons Of Mrna Vaccine from Different Manufactures
Wang, Y., & Zou, X. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v45i.7392
Hannawi, S., Villalobos, R. E., Burhan, E., Borra, M. D. L., Gupta, R. K., Aquitania, G. P., Ang, B. W., Zabat, G. M. A., Camilo C. Roa, Jr., Jesus, L. Z. D., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4689124
Self-citationMattos, R., Fioretto, M. N., dos Santos, S. A. A., Ribeiro, I. T., Emílio-Silva, M. T., Portela, L. M. F., Hiruma-Lima, C. A., Seiva, F. R. F., & Justulin, L. A. (2025) · Biogerontology · doi:10.1007/s10522-025-10251-w
Wu, M., Luo, X., Jiang, P., Xu, Q., Du, F.-X., Chen, X., Feng-qin, Y., Cui, Z., Li, Y.-Y., Chen, J.-Y., et al. (2026) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-026-13893-z
Self-citation
- Authors
- Zhao, H., Wang, T.-C., Li, X.-F., Zhang, N.-N., Li, L., Zhou, C., Deng, Y.-Q., Cao, T.-S., Yang, G., Li, R.-T., Huang, Y.-J., Li, Y.-G., Zhang, Y.-M., Li, F.-X., Zhou, Y.-R., Jiang, Y.-H., Lu, X.-S., Sun, S.-H., Cheng, M.-L., Gu, K.-P., Zhang, M., Ma, Q.-Q., Yang, X., Ying, B., Gao, Y.-W., & Qin, C.-F.
- Affiliations
- Academy of Military Medical Sciences (CN)
- Beijing Proteome Research Center (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Ying, Bo
- Qin, Cheng-Feng
- ORCID
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2021-12-24
- Volume
- 6
- Issue
- 1
- Pages
- 438-438
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC8703211
- OpenAlex
- W4200134232
- Cited by
- 60
- References
- 40
- Citations by year
- 2026: 3 · 2025: 17 · 2024: 10 · 2023: 19 · 2022: 10 · 2021: 1
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82041044, 2021YFC0863300, 81 621 005, 81925025, 32130005)
- Chinese Academy of Medical Sciences (2019-I2M-5-049)
- National Science Fund for Distinguished Young Scholars (81925025, 2019-I2M-5-049, 81621005)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Keywords
- COVID-19 mRNA vaccine, SARS-CoV-2 receptor-binding domain, cynomolgus macaques, neutralizing antibodies, antibody-dependent enhancement, vaccine storage stability, intramuscular vaccination
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, Animals, Antibodies, Viral, Chlorocebus aethiops, Humans, Macaca fascicularis, Vero Cells, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
